Jump to:
Abingdon Health PLC Fundamentals
| Company Name | Abingdon Health PLC | Last Updated | 2024-04-24 |
|---|
| Industry | Diagnostics & Research | Sector | Healthcare |
|---|
| Shares in Issue | 121.717 m | Market Cap | £12.59 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.01 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0.2090 | Debt Equity Ratio | 0.5022 |
|---|
| Asset Equity Ratio | 2.6582 | Cash Equity Ratio | 1.1014 |
|---|
| Quick Ratio | 1.4292 | Current Ratio | 1.79 |
|---|
| Price To Book Value | 7.0472 | ROCE | 0 |
|---|
Abingdon Health PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Abingdon Health PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|
| Tangible Assets | £1.21 m | £1.78 m | £9.04 m |
| Intangible Assets | £90,000.00 | £36,000.00 | £1.23 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £1.30 m | £1.81 m | £10.27 m |
| Stocks | £329,000.00 | £534,000.00 | £7.89 m |
| Debtors | £1.10 m | £7.14 m | £9.58 m |
| Cash & Equivalents | £3.24 m | £2.40 m | £4.98 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £6.06 m | £12.77 m | £33.23 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|
| Creditors within 1 year | £2.12 m | £5.32 m | £10.76 m |
| Creditors after 1 year | £932,000.00 | £1.01 m | £1.14 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £3.05 m | £6.34 m | £11.90 m |
| Net assets | £3.01 m | £6.43 m | £21.33 m |
| Equity | 2023 | 2022 | 2021 |
|---|
| Called up share capital | £31,000.00 | £31,000.00 | £24,000.00 |
| Share Premium | £30.31 m | £30.31 m | £24.18 m |
| Profit / Loss | -£3.56 m | -£21.59 m | -£6.95 m |
| Other Equity | £3.01 m | £6.43 m | £21.33 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £3.01 m | £6.43 m | £21.33 m |
| Ratios | 2023 | 2022 | 2021 |
|---|
| Debt Ratio | £0.24 | £0.14 | £0.05 |
| Debt-to-Equity | £0.31 | £0.16 | £0.05 |
| Assets / Equity | 2.6582 | 2.6582 | 2.6582 |
| Cash / Equity | 1.1014 | 1.1014 | 1.1014 |
| EPS | -£0.01 | -£0.04 | -£0.02 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|
| Cash from operating activities | £913,000.00 | -£7.74 m | -£12.88 m |
| Cashflow before financing | £906,000.00 | -£1.82 m | £7.86 m |
| Increase in Cash | £839,000.00 | -£2.58 m | £589,000.00 |
| Income | 2023 | 2022 | 2021 |
|---|
| Turnover | £4.04 m | £2.83 m | £11.62 m |
| Cost of sales | £1.97 m | £6.43 m | £7.47 m |
| Gross Profit | £2.08 m | -£3.59 m | £4.14 m |
| Operating Profit | -£3.57 m | -£21.53 m | -£6.72 m |
| Pre-Tax profit | -£3.56 m | -£21.59 m | -£6.95 m |
Abingdon Health PLC Company Background
| Sector | Healthcare |
|---|
| Activities | Abingdon Health PLC is a technology-enabled lateral flow diagnostics company. It provides rapid testing solutions to clients in healthcare and other industries. The firm's product ABC-19 is an antibody test for Covid-19 , and also producestests covering areas such as self-test HIV, equine infection, human fertility, etc. Business operating segments includes; Contract Development comprises development work for third parties. Contract Manufacturing comprises contract development and manufacturing activities. Product Sales comprises the sale of ABC-19, Pocket Diagnostic products, PCRD tests and antibodies for research use. Key revenue comes from Contract Development segment. Geographically it operates and earns revenue from the UK, USA and Canada, Europe and the rest of the world. |
|---|
| Latest Interim Date | 14 Mar 2024 |
|---|
| Latest Fiscal Year End Date | 17 Oct 2023 |
|---|
Abingdon Health PLC Directors
| Appointed | Name | Position |
|---|
| 2023-10-25 | Dr. Christopher William Hand | Non-Executive Director,Chairman |
| 2023-10-24 | Mr. Chris Henry Francis Yates | Executive Director,Chief Executive Officer |
| 2023-10-18 | Ms. Melanie Ross | Executive Director,Chief Financial Officer and Company Secretary |
| 2021-11-29 | Mr. Scott Andrew Page | Company Secretary |
Abingdon Health PLC Contact Details
Abingdon Health PLC Advisors
